Catherine Koss MD
Clinical Fellow, Internal Medicine, UCSF School of Medicine
Join to View Full Profile
Ucsf Department Of Medicine505 Parnassus AvenueSan Francisco, CA 94143
Phone+1 415-476-1528
Are you Dr. Koss?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Catherine Koss, MD is an infectious disease specialist in San Francisco, California. She is currently licensed to practice medicine in California. She is a Clinical Fellow at UCSF School of Medicine.
Education & Training
University of California (San Francisco)Fellowship, Infectious Disease, 2012 - 2014- University of California (San Francisco)Residency, Internal Medicine, 2009 - 2012
Northwestern University The Feinberg School of MedicineClass of 2009
Certifications & Licensure
CA State Medical License 2011 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- 1 citationsLong-acting preexposure prophylaxis: early data on roll-out in the United States.Catherine A Koss, Urvi M Parikh
Current Opinion in HIV and AIDS. 2025-01-01 - 5 citationsDynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension.Moses R Kamya, Laura B Balzer, James Ayieko, Jane Kabami, Elijah Kakande
The Lancet. HIV. 2024-11-01 - 1 citationsFirst Case of HIV Seroconversion With Integrase Resistance Mutations on Long-Acting Cabotegravir for Prevention in Routine Care.Catherine A Koss, Monica Gandhi, Elias K Halvas, Hideaki Okochi, Carolyn Chu
Open Forum Infectious Diseases. 2024-09-01
Press Mentions
- Social Networks Key to PrEP Uptake in Rural Kenya and UgandaMarch 11th, 2021
Universal Access to Preventive Drugs Could Reduce HIV Incidence in Sub-Saharan AfricaFebruary 9th, 2021- FDA Should Help Defeat Another Viral Epidemic—HIV—by Reclassifying PrEP and PEP over the CounterJuly 9th, 2020
- Join now to see all
